share_log

T2 Biosystems | 4: Statement of changes in beneficial ownership of securities-Officer Sprague John M

SEC ·  Feb 21 05:06

Summary by Futu AI

John M. Sprague, the Chief Financial Officer of T2 Biosystems, Inc. (TTOO), executed a transaction on February 20, 2024, involving the acquisition of 40 shares of common stock. The transaction, classified under the code 'M', indicates an exercise or conversion of derivative security. Following this transaction, Sprague's direct holdings in the company increased to a total of 112 shares of common stock. The action reflects a continued investment by the CFO in the company, signaling potential confidence in T2 Biosystems' future performance.
John M. Sprague, the Chief Financial Officer of T2 Biosystems, Inc. (TTOO), executed a transaction on February 20, 2024, involving the acquisition of 40 shares of common stock. The transaction, classified under the code 'M', indicates an exercise or conversion of derivative security. Following this transaction, Sprague's direct holdings in the company increased to a total of 112 shares of common stock. The action reflects a continued investment by the CFO in the company, signaling potential confidence in T2 Biosystems' future performance.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.